Piezo-101

Phase 1

PPiezo Therapeutics, Inc.

Piezo-101 is one of 3 therapeutic programs targeting Skin Aging. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Skin AgingNot yet recruiting

Skin AgingPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Skin Aging

#DrugCompanyPhaseTrials

Retin-a

VValeant Pharmaceuticals

Preclinical

—2

Botox

RRevance Therapeutics, Inc.

Preclinical

—3

Piezo-101

PPiezo Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Skin Aging

NCT07671027

Clinical

Trials by Indication[1]

Skin Aging1 trial

An Open-Label, Within Participant-Controlled, First-in-Human (FIH) Study to Explore the Safety, Tolerability, and Pharmacodynamic Effects of PIEZO-101, an Investigational Plasmid DNA Biostimulator Delivered by Intradermal Electroporation to the Knee and Décolleté Regions in Healthy Adult Female Participants

Not yet recruiting·PPiezo Therapeutics, Inc.·Phase 1·NCT07671027·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Piezo-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Piezo-101. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Piezo Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: PPiezo Therapeutics, Inc.

Piezo-101

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Skin Aging1 trial

References

Drug Info

Quick Facts

Related News